Cargando…

PARP inhibitors in gastric cancer: beacon of hope

Defects in the DNA damage response (DDR) can lead to genome instability, producing mutations or aberrations that promote the development and progression of cancer. But it also confers such cells vulnerable to cell death when they inhibit DNA damage repair. Poly (ADP-ribose) polymerase (PARP) plays a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yali, Zheng, Kun, Huang, Yongbiao, Xiong, Hua, Su, Jinfang, Chen, Rui, Zou, Yanmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228511/ https://www.ncbi.nlm.nih.gov/pubmed/34167572 http://dx.doi.org/10.1186/s13046-021-02005-6

Ejemplares similares

PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer
por: Wang, Yali, et al.
Publicado: (2021)

Lactate Dehydrogenase: The Beacon of Hope?
por: Pandarathodiyil, Anitha Krishnan, et al.
Publicado: (2022)

NORD. A beacon of hope for people with rare disorders
por: Putkowski, Stefanie
Publicado: (2010)

Cellular immunotherapy as a beacon of hope for hematological malignancies
por: Lee, Hyun-Ju, et al.
Publicado: (2015)

H-FABP: A beacon of hope for prediabetic heart disease
por: Ramesh, Priyamvadha, et al.
Publicado: (2020)

“A beacon of hope for relapsed multiple myeloma patients: TALVEY™”
por: Khaliq, Nawal, et al.
Publicado: (2023)

Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer
por: Tariq, Syed Maaz, et al.
Publicado: (2018)

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
por: Chen, Hongjie, et al.
Publicado: (2023)

Adoptive NK Cell Therapy - a Beacon of Hope in Multiple Myeloma Treatment
por: Vu, Son Hai, et al.
Publicado: (2023)

Bioinformatics analysis identifies COL1A1, THBS2 and SPP1 as potential predictors of patient prognosis and immunotherapy response in gastric cancer
por: Wang, Yali, et al.
Publicado: (2021)

CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma
por: Su, Jinfang, et al.
Publicado: (2022)

PARP inhibition in breast cancer: progress made and future hopes
por: Tung, Nadine, et al.
Publicado: (2022)

Acute normovolemic hemodilution for major cancer surgeries during the COVID-19 pandemic: A beacon of hope
por: Ni, Yan, et al.
Publicado: (2020)

Electroconvulsive therapy in treatment resistant schizophrenia: Old beacon of hope when nothing else works
por: Adão, C., et al.
Publicado: (2022)

Silencing of CHFR Sensitizes Gastric Carcinoma to PARP Inhibitor Treatment
por: Li, Yuan, et al.
Publicado: (2019)

Radar beacons
por: Roberts, Arthur
Publicado: (1947)

The Beacon Light
Publicado: (1924)

#BeaconsOfLight
por: Drazner, Mark H.
Publicado: (2021)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods
por: Hu, Hongye, et al.
Publicado: (2020)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
por: Gao, Lili, et al.
Publicado: (2021)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Inhibition of c‐MET increases the antitumour activity of PARP inhibitors in gastric cancer models
por: Koustas, Evangelos, et al.
Publicado: (2020)

KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
por: Wu, Yong, et al.
Publicado: (2023)

Molecular Beacons in Diagnostics
por: Tyagi, Sanjay, et al.
Publicado: (2012)

PARP inhibitors: its role in treatment of cancer
por: Chen, Alice
Publicado: (2011)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

An update on PARP inhibitors for the treatment of cancer
por: Benafif, Sarah, et al.
Publicado: (2015)

PARP inhibitor combinations in prostate cancer
por: Pezaro, Carmel
Publicado: (2020)

PARP Inhibitors in Prostate and Urothelial Cancers
por: Garje, Rohan, et al.
Publicado: (2020)

PARP and PARG inhibitors in cancer treatment
por: Slade, Dea
Publicado: (2020)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

Advances in PARP Inhibitors for Prostate Cancer
por: Tisseverasinghe, Steven, et al.
Publicado: (2023)

PARP inhibitors in metastatic prostate cancer
por: Taylor, Amy K., et al.
Publicado: (2023)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

Advances in using PARP inhibitors to treat cancer
por: Kummar, Shivaani, et al.
Publicado: (2012)

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o9oqi3dbeeqaptaae2bdjh9gua